DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
Merrem PWS IV- Drug Insight, 2019
US$ 1,000.00
... Coverage of the Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY ...
January 2019
35 pages
Metgluco- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Metgluco ...
January 2019
35 pages
Methycobal Tablets- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Methycobal Tablets ...
January 2019
35 pages
Mezavant Xl- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mezavant ...
January 2019
35 pages
Minerva - API Insight, 2019
US$ 500.00
... patent expiry details with respect to Minerva API intelligence over Minerva and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2019
30 pages
Minerva-35- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Minerva ...
January 2019
35 pages
Mucodyne- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mucodyne ...
January 2019
35 pages
Mucosta- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mucosta ...
January 2019
35 pages
Multaq- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Multaq ...
January 2019
35 pages
Mycamine- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mycamine ...
January 2019
35 pages
Myfortic- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Myfortic ...
January 2019
35 pages
Namenda- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Namenda ...
January 2019
35 pages
Narcolepsy- Market Insight, Epidemiology and Market Forecast - 2028
US$ 6,250.00
... Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Narcolepsy Report Assessment Current Treatment Practices Unmet Needs Detailed Pipeline Product Profiles Market Attractiveness Market Drivers and Barriers KEY BENEFITS ...
January 2019
100 pages
Nebivololo Mylan- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nebivololo Mylan ...
January 2019
35 pages
Nesina- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nesina ...
January 2019
35 pages
Neurontin- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Neurontin ...
January 2019
35 pages
Nexavar- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nexavar ...
January 2019
35 pages
Nexium - API Insight, 2019
US$ 500.00
... patent expiry details with respect to Nexium API intelligence over Nexium and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2019
30 pages
Nexium-Mups- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nexium-Mups ...
January 2019
35 pages
Nexplanon- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nexplanon ...
January 2019
35 pages
Niaspan LP- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Niaspan ...
January 2019
35 pages
Norvasc- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Norvasc ...
January 2019
35 pages
Norvir SEC- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Norvir SEC ...
January 2019
35 pages
Novothyrox- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Novothyrox ...
January 2019
35 pages
Nuvaring- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nuvaring ...
January 2019
35 pages
Nuvigil- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nuvigil ...
January 2019
35 pages
Onglyza- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Onglyza ...
January 2019
35 pages
Onitsit- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Onitsit ...
January 2019
35 pages
Opana ER- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Opana ...
January 2019
35 pages
Optruma- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Optruma ...
January 2019
35 pages
Pariet- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Pariet ...
January 2019
35 pages
Pentasa Enema- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Pentasa Enema ...
January 2019
35 pages
Plavix- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Plavix ...
January 2019
35 pages
Pletal- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Pletal ...
January 2019
35 pages
Prezista- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Prezista ...
January 2019
35 pages
Prilosec- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Prilosec ...
January 2019
35 pages
Pristiq- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Pristiq ...
January 2019
35 pages
Proemend- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Proemend ...
January 2019
35 pages
Prograf- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Prograf ...
January 2019
35 pages
Propecia- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Propecia ...
January 2019
35 pages
Proscar- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Proscar ...
January 2019
35 pages
Pulmicort Turbuhaler- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Pulmicort Turbuhaler ...
January 2019
35 pages
Qvarspray- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Qvarspray ...
January 2019
35 pages
Ranexa- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Ranexa ...
January 2019
35 pages
Rapamune- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Rapamune ...
January 2019
35 pages
Recalbon- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Recalbon ...
January 2019
35 pages
Relpax- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Relpax ...
January 2019
35 pages
Remodulin- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Remodulin ...
January 2019
35 pages
Restex- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Restex ...
January 2019
35 pages